Kailera Therapeutics, Inc. (KLRA) Stock Forecast & Price Target

Kailera Therapeutics, Inc. (KLRA) has an ST Score of 64.3 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Our ST Score grades it B (64.3/100). The ST Score is a data-driven signal, not a recommendation.

Valuation A, Profitability B+, Financial Strength A, Momentum D, Growth C-, Forecast A.

Kailera Therapeutics, Inc. (KLRA) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Kailera Therapeutics, Inc. (KLRA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Kailera Therapeutics, Inc. (KLRA) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Kailera Therapeutics, Inc. (KLRA) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Kailera Therapeutics, Inc. (KLRA) is $42.00, which is +225.8% versus the recent price of $12.89.